However, in contrast to AMD, where anti-VEGF therapy effectively targets the neovascular process, its role in neovascular cCSC is less clear due to variable and often incomplete treatment responses [10,11,12,13], raising questions about whether fluid accumulation is primarily neovascular or a consequence of CSC-specific choroidal dysfunction. This evidence concerns the gene VEGFA and age-related macular degeneration.